Andere Kunden interessierten sich auch für
![Therapeutic Antibodies]( "Therapeutic Antibodies")
Therapeutic Antibodies150,99 €![Inhibitorinzidenz bei Hämophilie A- und B-Patienten]( "Inhibitorinzidenz bei Hämophilie A- und B-Patienten")
Inhibitorinzidenz bei Hämophilie A- und B-Patienten59,00 €![Anticarbohydrate Antibodies]( "Anticarbohydrate Antibodies")
Anticarbohydrate Antibodies110,99 €![Antibody Engineering Volume 1]( "Antibody Engineering Volume 1")
Antibody Engineering Volume 1221,99 €![Janeway Immunologie]( "Janeway Immunologie")
Janeway Immunologie109,99 €![Immunologie für Einsteiger]( "Immunologie für Einsteiger")
Immunologie für Einsteiger39,99 €![Antikörper in der Krebsbekämpfung]( "Antikörper in der Krebsbekämpfung")
Antikörper in der Krebsbekämpfung44,99 €
This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a competitively priced softcover edition. It includes general chapters presenting established technologies and clinical applications, chapters on emerging technologies, new therapeutic concepts, and clinical studies and detailed and specific information about currently approved therapeutic antibodies, including clinical data.
Nearly 100 international experts and researchers from academia, industry, and such regulating bodies as the FDA have contributed to this work. Includes are also information on intellectual property issues, hardly available elsewhere.
A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
From the foreword by Mark Glassy, Chairman & Professor, The Rajko Medenica Research Foundation, and Chief Executive Officer, Shantha West, Inc., San Diego, CA, USA:
"After more than a century of intense analysis, antibodies continue to amaze and inspire. This Handbook of Therapeutic Antibodies is not just an assembly of articles but rather a state-of-the-art comprehensive compendium, which will appeal to all those interested in antibodies, whether from academia, industry, or the clinic. It is an unrivalled resource which shows how mature the antibody field has become and how precisely the antibody molecule can be manipulated and utilized."
Stefan Dübel studied biology at the universities of Mainz and Heidelberg, initially concentrating on developmental biology. From 1989 onwards he carried out pioneering work on antibody phage display and antibody libraries with randomised CDRs. Further work focussed on antibody fusion proteins and improvements of antibody phage display. Currently he is Director of the Department of Biotechnology at the Technical University of Braunschweig and coordinator of the 'Antibody Factory' within the German NationalGenome Research Network. Stefan Dübel has co-authored a number of textbooks, about 90 publications and 15 patents in the field of recombinant antibodies and phage display.
Nearly 100 international experts and researchers from academia, industry, and such regulating bodies as the FDA have contributed to this work. Includes are also information on intellectual property issues, hardly available elsewhere.
A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
From the foreword by Mark Glassy, Chairman & Professor, The Rajko Medenica Research Foundation, and Chief Executive Officer, Shantha West, Inc., San Diego, CA, USA:
"After more than a century of intense analysis, antibodies continue to amaze and inspire. This Handbook of Therapeutic Antibodies is not just an assembly of articles but rather a state-of-the-art comprehensive compendium, which will appeal to all those interested in antibodies, whether from academia, industry, or the clinic. It is an unrivalled resource which shows how mature the antibody field has become and how precisely the antibody molecule can be manipulated and utilized."
Stefan Dübel studied biology at the universities of Mainz and Heidelberg, initially concentrating on developmental biology. From 1989 onwards he carried out pioneering work on antibody phage display and antibody libraries with randomised CDRs. Further work focussed on antibody fusion proteins and improvements of antibody phage display. Currently he is Director of the Department of Biotechnology at the Technical University of Braunschweig and coordinator of the 'Antibody Factory' within the German NationalGenome Research Network. Stefan Dübel has co-authored a number of textbooks, about 90 publications and 15 patents in the field of recombinant antibodies and phage display.